After Esperion commented on the FDA minutes from a Phase II meeting, Stifel says that the FDA has "left the door open" to approve Esperion;s ETC-1002 drug for "truly statin intolerant patients." The firm says that the potential market for the drug has increased by 40%. It keeps a Buy rating on the shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here